I'm hoping for opinions (not asking for any dd that hasn't already been done) about how an Apabetalone success might affect AMRN and Vascepa. Are they competitive or complementary?

My opinion, fwiw, is that right now it's very hard to tell. Vascepa may have benefits far beyond the indications for which it has been tested. The EVAPORATE trial - later this year - will be a start on clarifying that, for better or for worse. Also, there is a "school" of thought that Vascepa does not work by lowering triglycerides, but that lowered triglycerides are a biomarker for lower systemic inflammation (SI), i.e. that Vascepa works directly on SI and not indirectly via lowering triglycerides. At least that's my understanding as one of the unwashed masses. 

TIA